News 06.01.2026 Schlieren, Switzerland, January 5, 2026- ImmunOs Therapeutics AG is pleased to announce that Hilmar Ebersbach, former Chief Scientific Officer of the Company, has been nominated as Chief Executive Officer, effective January 2026. Hilmar brings deep scientific expertise, a strong track record in drug discovery including translational development as well as...
News 22.12.2025 Zurich, Switzerland – 05. December 2025 A game changer for the next generation of circular makers: Swiss cleantech startup KUORI is shaking up the world of material and product design with the launch of a 3D printing filament based on its flagship material BIOWA, a bio-based, biodegradable and recyclable thermoplastic...
News 18.12.2025 Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the...
News 17.12.2025 Zurich, Switzerland - Topadur Pharma AG, a clinical-stage biotechnology company developing innovative therapies for vascular regeneration, today announced the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer. Dr. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO and now assumes executive leadership as the company advances...
News 15.12.2025 DINAMIQS, a Siegfried company, today announced a licensing agreement with ExcellGene to access its HEKExpress® and HEK2Express® suspension cell line technologies. These will be used in GMP manufacturing of recombinant Adeno-associated virus (rAAV) and Lentivirus (rLV) vectors for both in-vivo and ex-vivo gene therapies. Eduard Ayuso, Chief Technical Officer at DINAMIQS:...